FACTORS MODIFYING BEHAVIORAL TOXICITY OF LEAD AND PCB'S

改变铅和多氯联苯行为毒性的因素

基本信息

  • 批准号:
    6340932
  • 负责人:
  • 金额:
    $ 13.44万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1999
  • 资助国家:
    美国
  • 起止时间:
    1999-04-20 至 2001-03-31
  • 项目状态:
    已结题

项目摘要

Lead (Pb) is a frequently encountered pollutant from superfund sites, urban and agricultural soils, and other hazardous wastes which may be ingested or inhaled, particularly by children. There is increasing evidence that low-level Pb exposure and even slight elevations in blood lead (BPb) level in early childhood are associated with significant, enduring, cognitive neurobehavioral deficits, thereby creating a pressing need both to reduce exposure to Pb and to develop more effective means of treating children with even slightly elevated BPb levels. One promising new therapeutic chelating agent, dimercaptosuccinic acid (DMSA), is highly effective in reducing BPb and tissue Pb levels, can be administered orally on an outpatient basis, and does not cause the many side effects associated with current chelation therapy. To date, no studies have examined either the efficacy of this compound in alleviating Pb neurobehavioral toxicity or the possible behavioral teratogenicity of DMSA itself. Such studies are essential before the drug can be approved for widespread use; moreover, these studies can provide additional insight into the extent and duration of these deficits and the applicability of this model as a probe for assessment of neurotoxicants in hazardous wastes. The major purpose of the proposed studies is to determine if chelation with DMSA lessens the neurobehavioral deficits associated with rodent models of either childhood and adult Pb exposure. Separate groups of animals will be subjected to Pb exposure po via a regime already established as to BPb levels and neonastal deficits. Pb-exposed animals and controls will be euthanized before and after the three DMSA regimens so that performance in the battery of neurobehavioral measures can be correlated with both brain and blood Pb levels. This proposed study is a continuation of neurobehavioral Pb toxicity studies under the Cornell Superfund Basic Research and Education Program and parallels two studies recently funded by NIEHS to examine the efficacy of DMSA in alleviating the neurobehavioral toxicity of Pb - a multicenter pediatric trial (RFP NIH-ES 92-93) and a similar study using a non-human primate model. The proposed project will cooperatively provide important information about the efficacy of DMSA in alleviating (or exacerbating) Pb-induced cognitive dysfunction that will not be provided by either of the parallel studies and therefore should aid in interpretation of their results. They in turn provide technical services assisting evaluation of Pb mitigation. Briefly, this project, relative to the two parallel studies, would provide (1) dose-response information about DMSA in alleviating Pb- induced cognitive dysfunction; (2) determination of DMSA efficacy as a function of BPb level under conditions in which Pb exposure and DMSA treatment can be carefully controlled and monitored, and sociodemographic factors affecting cognition can be controlled; (3) the relationship between changes in neurobehavioral function and brain Pb levels; and (4) assessment of DMSA efficacy in alleviating neurobehavioral deficits in cases of adult Pb exposure.
铅(Pb)是超级基金场址常见的污染物,

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

BARBARA J STRUPP其他文献

BARBARA J STRUPP的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('BARBARA J STRUPP', 18)}}的其他基金

Perinatal choline therapy in a mouse model of Down Syndrome & Alzheimer's Disease
唐氏综合症小鼠模型的围产期胆碱治疗
  • 批准号:
    7362953
  • 财政年份:
    2008
  • 资助金额:
    $ 13.44万
  • 项目类别:
Perinatal choline therapy in a mouse model of Down Syndrome & Alzheimer's Disease
唐氏综合症小鼠模型的围产期胆碱治疗
  • 批准号:
    7760908
  • 财政年份:
    2008
  • 资助金额:
    $ 13.44万
  • 项目类别:
Perinatal choline therapy in a mouse model of Down Syndrome & Alzheimer's Disease
唐氏综合症小鼠模型的围产期胆碱治疗
  • 批准号:
    8049067
  • 财政年份:
    2008
  • 资助金额:
    $ 13.44万
  • 项目类别:
Perinatal choline therapy in a mouse model of Down Syndrome & Alzheimer's Disease
唐氏综合症小鼠模型的围产期胆碱治疗
  • 批准号:
    7568186
  • 财政年份:
    2008
  • 资助金额:
    $ 13.44万
  • 项目类别:
Perinatal choline therapy in a mouse model of Down Syndrome & Alzheimer's Disease
唐氏综合症小鼠模型的围产期胆碱治疗
  • 批准号:
    8211029
  • 财政年份:
    2008
  • 资助金额:
    $ 13.44万
  • 项目类别:
PRENATAL COCAINE EXPOSURE AND ATTENTIONAL DYSFUNCTION
产前接触可卡因和注意力功能障碍
  • 批准号:
    6858753
  • 财政年份:
    2002
  • 资助金额:
    $ 13.44万
  • 项目类别:
PRENATAL COCAINE EXPOSURE AND ATTENTIONAL DYSFUNCTION
产前接触可卡因和注意力功能障碍
  • 批准号:
    6619545
  • 财政年份:
    2002
  • 资助金额:
    $ 13.44万
  • 项目类别:
PRENATAL COCAINE EXPOSURE AND ATTENTIONAL DYSFUNCTION
产前接触可卡因和注意力功能障碍
  • 批准号:
    6711679
  • 财政年份:
    2002
  • 资助金额:
    $ 13.44万
  • 项目类别:
PRENATAL COCAINE EXPOSURE AND ATTENTIONAL DYSFUNCTION
产前接触可卡因和注意力功能障碍
  • 批准号:
    6435444
  • 财政年份:
    2002
  • 资助金额:
    $ 13.44万
  • 项目类别:
FACTORS MODIFYING BEHAVIORAL TOXICITY OF LEAD AND PCB'S
改变铅和多氯联苯行为毒性的因素
  • 批准号:
    6106346
  • 财政年份:
    1999
  • 资助金额:
    $ 13.44万
  • 项目类别:

相似海外基金

Investigating paradoxical YAP activation as an emergent limitation to Cu chelation therapy in BRAF V600E-driven melanoma
研究矛盾的 YAP 激活作为 BRAF V600E 驱动的黑色素瘤中铜螯合疗法的紧急限制
  • 批准号:
    9982040
  • 财政年份:
    2019
  • 资助金额:
    $ 13.44万
  • 项目类别:
Metals in the Trial to Assess Chelation Therapy 2 (TACT2M)
评估螯合疗法 2 试验中的金属 (TACT2M)
  • 批准号:
    10388645
  • 财政年份:
    2016
  • 资助金额:
    $ 13.44万
  • 项目类别:
Metals in the Trial to Assess Chelation Therapy 2 (TACT2M)
评估螯合疗法 2 试验中的金属 (TACT2M)
  • 批准号:
    9688920
  • 财政年份:
    2016
  • 资助金额:
    $ 13.44万
  • 项目类别:
Metals in the Trial to Assess Chelation Therapy 2 (TACT2M)
评估螯合疗法 2 试验中的金属 (TACT2M)
  • 批准号:
    9196058
  • 财政年份:
    2016
  • 资助金额:
    $ 13.44万
  • 项目类别:
Metals in the Trial to Assess Chelation Therapy 2 (TACT2M)
评估螯合疗法 2 试验中的金属 (TACT2M)
  • 批准号:
    10254152
  • 财政年份:
    2016
  • 资助金额:
    $ 13.44万
  • 项目类别:
Trial to Assess Chelation Therapy 2 (TACT2) DCC
评估螯合疗法 2 (TACT2) DCC 的试验
  • 批准号:
    9182074
  • 财政年份:
    2015
  • 资助金额:
    $ 13.44万
  • 项目类别:
Trial to Assess Chelation Therapy 2- TACT2 CCC
评估螯合疗法 2- TACT2 CCC 的试验
  • 批准号:
    9551736
  • 财政年份:
    2015
  • 资助金额:
    $ 13.44万
  • 项目类别:
Trial to Assess Chelation Therapy 2 (TACT2) DCC
评估螯合疗法 2 (TACT2) DCC 的试验
  • 批准号:
    9144715
  • 财政年份:
    2015
  • 资助金额:
    $ 13.44万
  • 项目类别:
Trial to Assess Chelation Therapy 2 (TACT2) DCC Supplemental Bridge Funding
评估螯合疗法 2 (TACT2) DCC 补充过渡资金的试验
  • 批准号:
    10393120
  • 财政年份:
    2015
  • 资助金额:
    $ 13.44万
  • 项目类别:
Trial to Assess Chelation Therapy 2- TACT2 CCC
评估螯合疗法 2- TACT2 CCC 的试验
  • 批准号:
    9693679
  • 财政年份:
    2015
  • 资助金额:
    $ 13.44万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了